PLX061388

GSE90728: Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer [NSCLC]

  • Organsim human
  • Type RNASEQ
  • Target gene
  • Project ARCHS4

Therapies that boost the anti-tumor responses of cytotoxic lymphocytes (CTLs) have shown promise in the clinic. However, clinical responses to currently available immunotherapeutic agents vary considerably, for which the molecular basis is unclear. To date, unbiased transcriptomic studies of CTLs in human cancers have been performed in whole tumors or cells obtained from peripheral blood or metastatic sites of heavily pre-treated patients. We performed global transcriptional profiling of CTLs in tumors and adjacent non-tumor tissue from treatment-nave patients with early stage lung cancer to define the molecular features associated with robustness of anti-tumor immune responses. We observed major differences in the transcriptional program of tumor-infiltrating CTLs that are shared across tumor subtypes. Pathway analysis revealed enrichment of genes in cell cycle, T cell receptor (TCR) activation and co-stimulation pathways, indicating tumor-driven expansion of presumed tumor antigen-specific CTLs. We also observed marked heterogeneity in the expression of molecules associated with TCR activation and immune checkpoints such as 4-1BB, PD1, TIM3, and their expression was positively correlated with the density of tumor-infiltrating CTLs. Interestingly, transcripts linked to tissue-resident memory cells (TRM), such as CD103, were enriched in tumors containing a high density of CTLs, and CTLs from CD103high tumors displayed features of enhanced cytotoxicity, implying better anti-tumor activity. In an independent cohort of 689 lung cancer patients, we confirmed that patients with CD103high (TRM rich) tumors survived significantly longer. In summary, we define the molecular fingerprint of tumor-infiltrating CTLs at the site of primary tumor and identify a number of novel targets that may be important in modulating the magnitude and specificity of anti-tumor immune responses in lung cancer. SOURCE: Pandurangan Vijayanand (vijay@lji.org) - La Jolla Institute for Allergy and Immunology

View on GEOView in Pluto

Key Features

Enhance your research with our curated data sets and powerful platform features. Pluto Bio makes it simple to find and use the data you need.

Learn More

14K+ Published Experiments

Access an extensive range of curated bioinformatics data sets, including genomic, transcriptomic, and proteomic data.

Easy Data Import

Request imports from GEO or TCGA directly within Pluto Bio. Seamlessly integrate external data sets into your workflow.

Advanced Search Capabilities

Utilize powerful search tools to quickly find the data sets relevant to your research. Filter by type, disease, gene, and more.

Analyze and visualize data for this experiment

Use Pluto's intuitive interface to analyze and visualize data for this experiment. Pluto's platform is equipped with an API & SDKs, making it easy to integrate into your internal bioinformatics processes.

Read about post-pipeline analysis

View QC data and experiment metadata

View quality control data and experiment metadata for this experiment.

Request import of other GEO data

Request imports from GEO or TCGA directly within Pluto Bio.

Chat with our Scientific Insights team